Topline Trader by Jason Stutman - Legit? [Honest Review]

Mark Charles · 2019-11-27T12:12:00+00:00

Looking for a review of Topline Trader? I've put together a review of Jason Stutman's Topline Trader sharing the pros and cons. Read it now before you join!

Looking for a review of the Topline Trader?

I recently started receiving email promotions for Project Greenlight which promotes Topline Trader so I’ve been taking a closer look.

I’ve put together an honest review sharing the pros and cons to give you an un-biased view of Topline Trader.

Keep reading below to get all the details!

Before I start…

If you’re tired of scams and want a real solution for making money online check out my recommendation below.

It’s helped me earn over $300k in the last 12 months alone:

Go here to see my no.1 recommendation for making money online

(This is a 100% free training)

Topline Trader Review

1 Topline Trader Review
2 Topline Trader Verdict
- 2.1 Before you leave

What Is Topline Trader?

Topline Trader is an investment advisory newsletter offered by Jason Stutman and published by Angel Publishing.

It was being promoted via the Project Greenlight website and is a limited time offer.

I’ve reviewed similar time sensitive promotions lately like Transform Your Life Summit and Rebound Profit Summit by Paul Mampilly.

The main focus of this newsletter is small-cap stocks in the biotech industry that are at the heart of key catalyst events that may trigger double or triple-digit gains.

Small companies are suited to individual investors because institutional investors cannot be involved with them and they don’t require an enormous investment.

Who is Jason Stutman?

Jason Stutman is the senior tech analyst at Angel Financial.

He lives by a simple trading philosophy; find a disruptor, buy shares, then sell them for a profit.

This strategy works nicely because of the fast-paced nature of the technology industry today.

It also enables him to scour the broader market in search of good investment opportunities.

He writes about the latest technological trends in advisory newsletters like Topline Trader and Technology and Opportunity.

How does Topline Trader Work?

Jason and his team of analysts have a way of identifying promising investment opportunities: They use a proprietary grading system called the Chance of Success (CoS).

This grading system rates the progress of the development of a drug, which is important because small biotech companies can explode in value if they release a successful drug.

CoS enables you to gauge the viability of companies that have drugs on their pipelines.

More importantly, it enables you to follow the companies that have good prospects and avoid wasting time on the duds (although you can make money by betting against them).

For example, when a small pharmaceutical company has had positive news with its drug trials and is likely to make it through approval, the CoS gives it a good rating thus allowing you to buy shares before it takes off.

The strategy is suited to both novice investors who only want to buy stock and veterans who aren’t afraid of dabbling in options.

In addition to receiving recommendations as a member of Topline Trader, you can request a CoS rating of any drug in development and they will gladly give it to you.

In addition to the Chance of Success rating system, Jason has a network of scientists and medical professionals who track drug development on your behalf.

This network gives Jason and his readers an insider’s scoop of what’s going on in the biotech industry.

These people have deep connections with the scientists behind some of the most notable medical discoveries.

Moreover, they can make sense of development data in ways that investors can’t. Jason pays top dollar for their insights because the return on investment justifies keeping them around.

What You Get When You Join Topline Trader

When you join this investment advisory service, you gain access to the following:

Trade alerts
Weekly Biotech Catalyst Alerts and Stock Analysis
Chance of Success ratings of every interesting company you can think of
An Interactive FDA and Drug Development Calendar
A collection of Company Reports and Analyses of Drug Development Trials
The Weekly “Grapevine” Feature: These are stocks that have been recommended through their network
Detailed coverage on stocks and drug trials

You also learn new options trading strategies if you are interested in them.

Subscription Fee

One year: $4,999.

Performance Guarantee

You are allowed a trial period of 30 days.

If it fails to impress you, you can ask for a full refund of your subscription fee.

Is Topline Trader a Scam?

Topline Trader is not a scam.

It is an investment service that targets small companies in the biotech sector.

It leverages a network of medical professionals, biotech insiders, market analysts, and a proprietary tool that predicts the viability of a company based on its drug development cycle.

It, therefore, does not perpetuate a get-rich-quick scheme.

Pros of Topline Trader

This newsletter enables Main Street investors to access a network of pharmaceutical insiders they would otherwise not be within earshot of in ordinary circumstances.
The CoS rating system provides a non-biased way of evaluating biotech stocks
By focusing on small companies, the upside potential is quite big. Bear in mind that small-cap stocks have historically outperformed large-cap stocks.

Cons of Topline Trader

The subscription fee of $4,999 is relatively steep for Main Street investors.

Topline Trader Verdict

Small biotech stocks that are on the cusp of developing breakout treatments or revolutionary products offer arguably the best opportunity to create generational wealth in a short period.

Events like FDA directives, regulatory filings, and licensing deals have big impacts on these small firms.

Due to the high volatility typical of these stocks, single events can trigger double or triple-digit swings in either direction – profit or loss.

With a system that can predict these stock swings, Topline Trader allows you to boost your portfolio with massive profit margins.

Although some of the predictions will not be accurate, you will be better off following Jason’s guidance in an industry he knows quite well.

Before you leave